Higher levels of TNF12 (tumor necrosis factor ligand superfamily member 12) decreased the risk of non-ischemic CM (OR, 0.82; 95% CI, 0.77 to 0.88) and DCM (OR, 0.80; 95% CI, 0.75 to 0.85). Here, TNFSF12 is linked to cutaneous mastocytosis.